Atea Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
225 Franklin St Ste 2100, Boston, Massac...Phone Number
(857) 284-8891Website
www.ateapharma.comRevenue
$25.3 MillionStock Symbol
AVIRIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Atea Pharmaceuticals
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Explore more
Atea Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Atea Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Atea Pharmaceuticals has new funding data
Check out if Atea Pharmaceuticals is spiking on competitors!
Click to see if Atea Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Atea Pharmaceuticals
Check if Atea Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Atea Pharmaceuticals recently announced quarterly report
Product Launch: Get notified when Atea Pharmaceuticals launches new products
Atea Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Atea Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Atea Pharmaceuticals
Compare insights from companies similar to Atea Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Atea Pharmaceuticals
$25.3M
51-200
Public
$591M
2012
AC
Andrea CorcoranChief Financial Officer & Executive VP, Legal
Company Profile Activity
Activity Insights
Atea Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Atea Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Atea Pharmaceuticals.
Atea Pharmaceuticals financials insights
Gather financial insights about Atea Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$20M
2016
Unspecified
$20.8M
2018
Unspecified
$27.6M
2019
Series B
$7.6M
2020
Series D
$215M
Stock Offering
$300M
Atea Pharmaceuticals Tech Stack
A closer look at the technologies used by Atea Pharmaceuticals
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Atea Pharmaceuticals has announced that H2 2026 is expected to be a catalyst-rich period, with top-line results from its Phase III HCV trial C-Beyond anticipated mid-year and top-line results from its Phase III HCV trial C-Forward expected around year-end 2026.
Pharmaceuticals, Clinical Operations
Project
Atea Pharmaceuticals has reported Phase II study results for its HCV treatment regimen showing a 98% sustained viral response rate at 12 weeks (SVR12) in treatment-adherent patients and a 95% SVR12 rate overall, with a favorable safety profile, reinforcing confidence in the ongoing Phase III program.
Medical Research, Pharmaceuticals
Project
Atea Pharmaceuticals has completed clinical trial application enabling studies for AT-587, its hepatitis E virus (HEV) product candidate, with preclinical results presented at CROI and EASL demonstrating high in vitro antiviral potency against HEV, supporting AT-587 as a potential first-in-class inhibitor for HEV infection.
Clinical Operations
Project
Medical Research, Pharmaceuticals
Atea Pharmaceuticals News & Media
Atea Pharmaceuticals Completes Patient Enrollment in Phase 3 C-FORWARD Trial Evaluating Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Topline Phase 3 Results from C-FORWARD Expected Around Year-End 2026Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026
Additional Data Presented Demonstrate High In Vitro Antiviral Potency and In Vivo Efficacy for AT-587, Atea’s Potential First-in-Class Direct-Acting Antiviral for the Treatment of Hepatitis E Virus Additional Data Presented Demonstrate High In Vitro Antiviral Potency and In Vivo Efficacy for AT-587, Atea’s Potential First-in-Class Direct-Acting Antiviral for the Treatment of Hepatitis E VirusAtea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain.Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Atea Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develop... Read More
